Conferences AASLD 2013
Other Infections
AASLD 2013: HCV Levels in Semen May Correspond to Blood Viral Load
- Details
- Category: HCV Prevention
- Published on Wednesday, 18 December 2013 00:00
- Written by Liz Highleyman
HIV positive men with higher hepatitis C virus (HCV) RNA levels in their blood during acute infection were more likely to have HCV in their semen as well, which may raise the risk of sexual transmission, researchers reported last month at the 64thAASLD Liver Meeting in Washington, DC.
AASLD 2013: Tenofovir for Hepatitis B Remains Safe and Effective Over 7 Years
- Details
- Category: HBV Treatment
- Published on Wednesday, 04 December 2013 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients treated with tenofovir (Viread) for 7 years continued to main viral suppression and liver enzyme normalization, while serological response rates continued to increase, according to a poster presented at the 64th AASLD Liver Meeting last month in Washington, DC. Long-term kidney and bone-related side effects remained uncommon.
AASLD 2013: Faldaprevir Triple Therapy Effective Across Patient Subgroups
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 27 November 2013 00:00
- Written by Michael Carter
The experimental hepatitis C virus (HCV) protease inhibitor faldaprevir in combination with pegylated interferon and ribavirin was effective across a range of subgroups of patients with genotype 1 infection -- including prior relapsers and non-responders -- in the STARTVerso clinical trials program, according to research presented at the recent AASLD Liver Meeting in Washington, DC.
AASLD 2013: MK-5172 + Ribavirin Works Well for People with Hepatitis C Genotype 1b
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 04 December 2013 00:00
- Written by Liz Highleyman
An interferon-free regimen consisting of Merck's next-generation hepatitis C virus (HCV) protease inhibitor MK-5172 plus ribavirin led to high rates of viral suppression and promising early cure rates for patients with HCV subtype 1b, according to a poster presented at the 64thAASLD Liver Meeting last month in Washington, DC.
AASLD 2013: Aspirin and Cenicriviroc May Help Reduce Liver Fibrosis
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 26 November 2013 00:00
- Written by Liz Highleyman
Hepatitis C patients who took low-dose aspirin after liver transplantation experienced slower fibrosis progression, researchers reported at the AASLD Liver Meeting this month in Washington, DC. Two other studies showed that cenicriviroc -- a drug being developed for HIV treatment that blocks both CCR5 and CCR2 cell surface receptors -- had anti-inflammatory and anti-fibrotic activity in mice and rats.
AASLD 2013: Sofosbuvir + Ribavirin Effective Against Hepatitis C Genotype 4
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 04 December 2013 00:00
- Written by Liz Highleyman
A dual oral regimen of sofosbuvir plus ribavirin taken for 24 weeks led to an early cure at 4 weeks post-treatment for difficult-to-treat patients with hepatitis C virus (HCV) genotype 4, according to a poster presented at the 64th AASLD Liver Meeting last month in Washington, DC.
AASLD 2013: Liver Meeting Ends with Hepatitis C Debrief and the Future of Treatment
- Details
- Category: HCV Treatment
- Published on Thursday, 21 November 2013 00:00
- Written by Liz Highleyman
The final day of AASLD Liver Meeting, recently held in Washington, DC, featured an overview of the status of new hepatitis C therapies, similarities between HCV and HIV, and a look towards the future of hepatitis C treatment. The development of next-generation HCV drugs has been remarkably rapid and experts agree that it may soon be possible to cure all patients with hepatitis C, but access is likely to be a challenge.
AASLD 2013: Viral Hepatitis Epidemics in the U.S. and California
- Details
- Category: HBV Epidemiology & Mortality
- Published on Wednesday, 27 November 2013 00:00
- Written by Liz Highleyman
Deputy Assistant Secretary for Health Ronald Valdisseri described the hepatitis B and C epidemics in the U.S., the HCV cascade of care, and efforts to combat viral hepatitis at the AASLD Liver Meeting this month in Washington, DC. Public health officials in California also recently released a report on the hepatitis B and C epidemics in that state.
AASLD 2013: Faldaprevir All-oral Regimen Shows 100% Early Sustained Response for HCV 1a
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 21 November 2013 00:00
- Written by Liz Highleyman
An interferon-free regimen of faldaprevir, deleobuvir, and PPI-668 led to 4-week post-treatment sustained virological response (SVR4) in all treatment-naive patients with hard-to-treat HCV subtype 1a in an ongoing Phase 2 trial, according to a late-breaking poster presentation at the 64th AASLD Liver Meeting this month in Washington, DC.
More Articles...
- AbbVie All-Oral Regimen Produces 96% Cure Rate, Effective Against Both HCV 1a and 1b
- AASLD 2013: Black Hepatitis C Patients Do Well on Sofosbuvir Oral Regimens
- AASLD 2013: Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity
- AASLD 2013: Hepatitis B Vaccine Protection Lasts at Least 30 Years
- AASLD 2013: Hepatitis C Treatment Reduces Liver Cancer and Death, But Most Remain Untreated
- AASLD 2013: Faldaprevir + Interferon/Ribavirin Leads to Early Sustained Response for HIV/HCV Coinfected
- AASLD 2013: Fixed-dose Sofosbuvir/Ledipasvir Cures Most Genotype 1 Hepatitis C
- AASLD 2013: Sofosbuvir + Ribavirin for 12 or 24 Weeks Cures Most Genotype 2-3 Hepatitis C Patients
- AASLD 2013: Daclatasvir + Asunaprevir Cures 85% of Genotype 1b Hepatitis C Patients in Japanese Study
- AASLD 2013: Simeprevir with Pegylated Interferon/ Ribavirin Cures Genotype 1 Hepatitis C in 80%
- AASLD 2013: Entecavir + Tenofovir Works Well for Hepatitis B Patients with Prior Treatment Failure
- AASLD 2013: Viral Hepatitis Is a Leading Cause of Death Worldwide
- AASLD 2013: Sofosbuvir Taken Before or After Liver Transplant Reduces HCV Recurrence
- AASLD 2013: Label Warnings, Counseling Do Not Eliminate Risk of Acetaminophen Toxicity
- AASLD 2013: Merck Interferon-free Regimen Shows High Hepatitis C Cure Rate in Early Study
- AASLD 2013: Hepatitis B Treatment with Entecavir or Tenofovir Lowers, But Does Not Eliminate, HCC Risk
- AASLD 2013: BMS Interferon-free Combo Cures Over 90% of Genotype 1 HCV in 12 Weeks
- AASLD 2013: Sofosbuvir + Ribavirin Produces Sustained Response in 76% of GT 1 HIV/HCV Coinfected Patients
- AASLD 2013: AbbVie's Dual Interferon-free Combination Cures Genotype 1b Hepatitis C in 95%
- AASLD 2013: Expanded Hepatitis C Screening Needed for Veterans, Baby Boomers, Pregnant Women
- AASLD 2013: Liver Meeting Opens with a Focus on Hepatitis C
- AASLD 2013: 100% of Hard-to-treat Patients Cured with Sofosbuvir/Ledipasvir + Ribavirin or GS-9669
- AASLD 2013: Veterans Study Supports CDC Recommendation to Screen Baby Boomers for Hep C
- AASLD 2013: High Response Rates with Telaprevir Triple Therapy for HIV+ Men with Acute Hepatitis C
- AASLD 2013: Simeprevir + Sofosbuvir Produces High Sustained Response Rates for Hard-to-treat Patients
- AASLD Liver Meeting Starts this Weekend in Washington, DC
- Coverage of the 2013 AASLD Liver Meeting
Web Design and Development by